Papademetriou Marianna, Popov Violeta
Gastroenterology, New York University School of Medicine, 220 First Avenue, New York, NY 10016, USA.
Division of Gastroenterology, NY VA Harbor Healthcare (Manhattan), New York University School of Medicine, 423 East 23rd Street, 15 North, New York, NY 10010, USA.
Gastrointest Endosc Clin N Am. 2017 Apr;27(2):245-256. doi: 10.1016/j.giec.2016.12.006.
Cost-effective therapies to address the growing epidemic of obesity are a leading priority in modern medicine. Intragastric balloons (IGBs) are one such option, with increased effectiveness compared with pharmacotherapy and lifestyle and a lower rate of adverse events than bariatric surgery. IGBs are endoscopically placed or swallowed space-occupying devices in the stomach. Three IGB systems were approved in 2015 to 2016 by the Food and Drug Administration for use in the United States, with more devices nearing approval. This paper reviews the adverse events and efficacy of IGBs, and practice setup, management of common complications, and dietary advice for patients.
应对日益严重的肥胖流行问题的经济高效疗法是现代医学的首要任务。胃内气球（IGB）就是这样一种选择，与药物治疗和生活方式干预相比，其有效性更高，且不良事件发生率低于减肥手术。IGB是通过内镜放置或吞咽的胃内占位装置。2015年至2016年，美国食品药品监督管理局批准了三种IGB系统用于美国，还有更多装置即将获批。本文综述了IGB的不良事件、疗效、实践设置、常见并发症的管理以及对患者的饮食建议。
